Cancer Epidemiol Biomarkers Prev by Bellcross, Cecelia A. et al.
Prevalence and Healthcare Actions of Women in a Large Health 
System with a Family History Meeting the 2005 USPSTF 
Recommendation for BRCA Genetic Counseling Referral
Cecelia A. Bellcross1, Steven Leadbetter2, Sharon Hensley Alford3, and Lucy A. Peipins2
1Department of Human Genetics, Emory University School of Medicine, Atlanta, Georgia
2Epidemiology and Applied Research Branch, Division of Cancer Prevention and Control, Centers 
for Disease Control and Prevention, Atlanta, Georgia
3Josephine Ford Cancer Center, Henry Ford Health Systems, Detroit, Michigan
Abstract
Background—In 2005, the United States Preventive Services Task Force (USPSTF) released 
guidelines which outlined specific family history patterns associated with an increased risk for 
BRCA1/2 mutations, and recommended at-risk individuals be referred for genetic counseling and 
evaluation for BRCA testing. The purpose of this study was to assess the prevalence of individuals 
with a USPSTF increased-risk family history pattern, the frequency with which specific patterns 
were met, and resulting healthcare actions among women from the Henry Ford Health System.
Methods—As part of a study evaluating ovarian cancer risk perception and screening, 2,524 
randomly selected participants completed a detailed interview (response rate 76%) from an initial 
eligible cohort of 16,720 women.
Results—Approximately 6% of participants had a family history fulfilling one or more of the 
USPSTF patterns. Although 90% of these women had shared their family history with their 
provider, less than 20% had been referred for genetic counseling and only 8% had undergone 
genetic testing. Caucasian women with higher income and education levels were more likely to 
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receive referrals. Among the 95 participants in the total study cohort who reported BRCA testing, 
78% did not have a family history that met one of the USPSTF patterns.
Conclusions—These results suggest a higher prevalence of women with an increased-risk 
family history than originally predicted by the USPSTF, and lack of provider recognition and 
referral for genetic services.
Impact—Improvements in healthcare infrastructure and clinician education will be required to 
realize population level benefits from BRCA genetic counseling and testing.
Introduction
It is estimated that 2% to 7% of breast cancers and 10% to 15% of ovarian cancers result 
from an inherited mutation in one of 2 breast/ovarian cancer susceptibility genes, BRCA1 
and BRCA2 (BRCA1/2) (1–3). Approximately 1 of 400 individuals in the general population, 
and 1 of 40 individuals of Ashkenazi Jewish descent carry a mutation in one of these genes 
(1, 2, 4). Women with BRCA1/2 mutations face lifetime risks for breast and ovarian cancer 
of approximately 40% to 60% and 20% to 40%, respectively (5). First-degree relatives of 
known mutation carriers are at 50% risk of inheriting the familial mutation. Management 
options for BRCA1/2 mutation carriers, such as prophylactic mastectomy, bilateral salpingo-
oophorectomy, and breast MRI, have been shown to reduce cancer incidence and mortality 
and improve the likelihood of early detection (6–15).
In 2005, the United States Preventive Services Task Force (USPSTF) released a 
recommendation regarding "Genetic Risk Assessment and BRCA Mutation Testing for 
Breast and Ovarian Cancer Susceptibility (16)." Focused on women without cancer, the 
USPSTF recommended that "women whose family history is associated with an increased 
risk for deleterious mutations in BRCA1 or BRCA2 genes be referred for genetic counseling 
and evaluation for BRCA testing (16)." The USPSTF further recommended against routine 
referral for women without an "increased-risk family history", concluding that the potential 
harms outweighed the benefits (16). While acknowledging there are no standardized referral 
criteria, they outlined specific family history patterns associated with an "increased-risk" for 
deleterious BRCA mutations (Table 1). The USPSTF estimated that 2% of adult women in 
the general population would have an increased-risk family history according to their 
definition (16).
Though not the stated intent, this estimate and these specific family history patterns appear 
in some measure to have been interpreted as a guide for public health activities and clinical 
implementation. However, there are limited data regarding the prevalence of women in the 
general population whose family history meets one or more of the USPSTF increased-risk 
patterns. This is in part because large population health surveys have not collected 
information on cancer history in second-degree relatives, or other features such as 
bilaterality, breast and ovarian cancer in the same individual, or Jewish ancestry. Two 
previous studies examined family history of breast/ovarian cancer in first-degree relatives 
only from the 2000 and 2005 National Health Interview Surveys (17, 18). In both cases, less 
than 1% of the population met "high-risk" criteria consistent with the USPSTF 
recommendations (17, 18). In contrast, 2 publications that evaluated cohorts using detailed 
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family history found that 7.5% to 12.4% of women met USPSTF "increased-risk" family 
history patterns (19, 20). These findings suggest that the original USPSTF approximation of 
2% may have been an underestimate, and underscores the importance of collecting detailed 
family history.
Recently, a Healthy People 2020 objective based on the USPSTF guidelines was established 
to increase the proportion of women with a family history of breast and/or ovarian cancer 
who receive genetic counseling (21). If use of these patterns truly identifies up to 12% of 
women as increased-risk, it might significantly impact efforts to achieve this goal as it is 
unlikely that the existing health-care infrastructure could provide appropriate cancer genetic 
counseling and risk assessment services on this scale (22). A better understanding of the 
prevalence of women meeting the USPSTF increased-risk family history patterns could help 
guide program and educational efforts surrounding the Healthy People 2020 objective.
In the current study, we evaluated the prevalence of individuals meeting one or more of the 
USPSTF increased-risk family history patterns among a cohort of women from a large 
health system. In addition, we examined whether participants had talked with their 
healthcare provider about their family history, been referred for genetic counseling, or had 
undergone BRCA testing. While other guidelines for BRCA counseling and testing exist, we 
elected to focus on the 2005 USPSTF guidelines for this analysis, as they are the only 
recommendations produced as a result of a systematic evidence review by an independent 
panel of healthcare experts, and as such carry significant weight with respect to population-
based health policy decisions.
These data provide new knowledge regarding the use of these services among individuals 
who are at increased risk for deleterious BRCA1/2 mutations according to the USPSTF-
defined family history patterns.
Materials and Methods
Study population, eligibility criteria, and design
We used data from a study conducted by the Centers for Disease Control and Prevention 
(CDC) that evaluated ovarian cancer risk perception and screening among women at high, 
elevated, and average risk of ovarian cancer in the Henry Ford Health System (HFHS; 
Detroit, MI). CATI-assisted telephone interviews were conducted between January 16 and 
December 13, 2008 among eligible women (≥ age 30 years, no previous history of ovarian 
cancer, or bilateral oophorectomy). The survey eligibility screener asked about personal 
history of breast or ovarian cancer, prior oophorectomy, and knowledge of breast and 
ovarian cancer among first- and second-degree relatives. For random sampling purposes, we 
classified women into 3 risk groups based on the number of first- and second-degree 
relatives with breast or ovarian cancer and personal history of breast cancer. HFHS 
administrative data identified 55,887 potential study participants, 20,483 underwent 
eligibility screening (36.7%), and 16,720 (81.6%) were deemed eligible. The CATI system 
randomly selected 3,307 women for participation in the study and 2,524 women were 
consented and interviewed (response rate 76.3%). Data collected included demographics; 
detailed cancer family history including relatedness, maternal/paternal lineage, diagnosis 
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age, bilaterality (breast), and Jewish heritage; and family history discussion with a 
healthcare provider, referral for genetic counseling, and BRCA testing. This study was 
approved by the Institutional Review Boards of the CDC and HFHS.
Classification using USPSTF patterns
We determined whether the participants without breast cancer met one or more of the 
USPSTF increased-risk family history patterns (hereafter referred to as patterns) as given in 
Table 1. The following adjustments were made to account for details not specified by 
USPSTF: (i) in situations satisfying patterns 2, 3, and 5 with 2 second-degree relatives, they 
were required to be from the same family side (i.e., both maternal or both paternal); (ii) for 
pattern 7, a history of male breast cancer in either a first- or second-degree relative was 
counted, and (iii) satisfying pattern 7 was also considered indicative of an increased-risk 
pattern for individuals of Jewish ancestry (16).
We defined a second set of participants who metUSPSTF patterns by including women with 
a personal history of breast cancer from the perspective of a hypothetical unaffected sister. 
For example, a subject with breast cancer at age 45 was considered as an unaffected woman 
having a sister with breast cancer at age 45. Although the USPSTF guidelines are directed 
toward women without a personal history of breast or ovarian cancer, exclusion of such 
individuals leads to an underestimate of the number of families at risk for a BRCA mutation. 
Similar arguments were made for their inclusion by McClain and colleagues (20) and 
Percich and colleagues (23).
Statistical analysis
Weighted study estimates compensated for oversampling of the high and elevated risk 
groups, whereas SUDAAN (24) accounted for the stratified sample design. Wald χ2 
statistics tested for any outcome or covariate distributional differences among various 
subpopulations. T statistics tested for differences between various subpopulations for 
specific categories of outcomes and covariates.
Results
Table 2 provides the prevalence of participants who met the increased-risk family history 
patterns as defined by the USPSTF. Approximately 5% of participants without breast cancer 
fit one or more of the USPSTF patterns, increasing to 6%, when participants with breast 
cancer were included from the perspective of a hypothetical unaffected sister. The most 
common pattern was a combination of breast and ovarian cancer among first- and second-
degree relatives, followed by 3 or more first- or second-degree relatives with breast cancer 
regardless of age at diagnosis. Less than 1.5% of the study population fit 2 or more of the 
patterns and less than 0.5% fit 3 or more.
Table 3 provides a breakdown of participants who talked with their healthcare provider 
about their family history, were referred for cancer genetic counseling, underwent BRCA 
testing, and reported a positive test result—according to whether they met a USPSTF 
increased-risk pattern. This evaluation involves 3 groups: all participants including women 
with a personal history of breast cancer from the perspective of a hypothetical unaffected 
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sister, only participants without breast cancer, and only participants with breast cancer. For 
all 3 groups, the percentage of women who had talked with a health-care provider about 
their family history was significantly higher among those who met a USPSTF pattern than 
those who did not (Wald χ2, P ≤ 0.01). Although approximately 90% of participants in all 3 
groups who met a USPSTF pattern talked with their provider about their family history, only 
13.6%, 19.5%, and 41.8%, respectively, were referred for cancer genetic counseling. 
Referral was significantly more likely among those who met a USPSTF pattern than among 
those who did not (Wald χ2, P ≤ 0.0001). Women with a personal history of breast cancer 
were more likely to report a genetic counseling referral, irrespective of whether they met a 
USPSTF pattern. For all 3 groups, participants who met a USPSTF pattern were also 
significantly more likely to have reported BRCA1/2 testing (Wald χ2, P ≤ 0.01), with the 
highest percentage (25.3%) among women with a personal history of breast cancer. The 
number of women reporting a positive BRCA1/2 test result was too small to accommodate 
meaningful comparisons.
Table 4 provides demographic characteristics of all study participants and of those without 
breast cancer meeting a USPSTF increased-risk pattern by genetic counseling referral status. 
The population is primarily white, married or partnered, well educated, and in the middle- to 
upper-income brackets. Significant demographic differences by referral status were noted. 
Participants receiving genetic counseling referrals were more likely to be under age 61, hold 
a graduate degree, and have household incomes of $75,000 or more, whereas those with at 
most a high school education or household incomes less than $35,000 were less likely to be 
referred. Among all study participants, racial differences were also noted, with non-Hispanic 
whites significantly more likely to be referred than non-Hispanic blacks.
Discussion
In this large cohort of women representing a primary care population, 5% of women without 
breast cancer met USPSTF-defined increased-risk family history patterns for BRCA1/2 
genetic counseling referral. When women with a personal history of breast cancer were 
included from the perspective of a hypothetical unaffected sister, 6% met one or more of the 
USPSTF patterns. These findings are consistent with previous studies suggesting a 
substantially higher percentage of women meeting these patterns than the original 2% 
estimated by the USPSTF (19, 20). Given that women with a previous oophorectomy or 
ovarian cancer were not included in the study cohort, it is possible that our results 
underestimate the true number of families in this health system who could potentially benefit 
from genetic counseling referral and consideration of BRCA1/2 testing.
Though the majority of women who met a USPSTF pattern had talked with their healthcare 
provider about their family history, less than 20% of these participants reported having been 
referred for genetic counseling. This is concerning as genetic counseling is readily available 
and a covered service within HFHS. In addition, of women who reported a family member 
with a positive BRCA1/2 test (n =23), only 26.8% had been referred and 24.6% had 
undergone testing. While the numbers are small, this is perhaps more concerning as it is 
these women who are at the highest risk to carry a mutation and for whom testing is most 
informative. Furthermore, preferential referral of women with higher incomes and level of 
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education suggest that perhaps it is the patient, rather than the clinician, who may be the 
driving force behind obtaining cancer genetic services. These combined results confirm 
previous studies suggesting a need to improve provider knowledge of BRCA1/2 and referral 
indications (25, 26).
Of participants without breast cancer meeting a USPSTF pattern who had been referred for 
genetic counseling, only 18.3% reported undergoing BRCA1/2 testing. This result is not 
unexpected as these individuals may learn that they are not appropriate candidates for 
testing, or may decline testing for personal reasons. However, less expected was the finding 
that among the 16 women without breast cancer meeting a USPSTF pattern who underwent 
BRCA1/2 testing, 31.3% had not received a genetic counseling referral.
Talking with a healthcare provider about family history, being referred for genetic 
counseling and undergoing BRCA1/2 testing were all significantly more likely in 
participants who met a USPSTF pattern compared with those who did not. However, among 
participants who were referred for genetic counseling (n = 226), or underwent BRCA1/2 
testing (n = 95), 77.8% did not meet a USPSTF pattern. It is important to note that this does 
not imply that referral and testing was inappropriate for these women. Rather, it suggests 
that use of the USPSTF increased-risk family history patterns may not be the most 
appropriate method to identify women who should receive genetic services. Potentially 
related is our finding that referral and testing were substantially higher among women with a 
personal history of breast cancer, regardless of whether they met a USPSTF pattern. These 
women are under the care of surgeons and oncologists, who tend to be more familiar with 
issues related to BRCA1/2 than family physicians or internists (26). Furthermore, it is well 
documented, and was noted by USPSTF, that testing is most informative if a mutation is 
first identified in an affected family member, and it is standard of care to offer testing to 
affected women with a reasonable likelihood of carrying a BRCA1/2 mutation (27, 28). 
Although small numbers, it is worth noting that of the 6 women with a personal history of 
breast cancer who reported having a "positive" BRCA1/2 test; only 2 met the USPSTF 
patterns even when considered from the perspective of a hypothetical unaffected sister. 
These findings likely reflect in part the use by providers of alternate and updated guidelines 
such as those of the National Comprehensive Cancer Network (NCCN), which include more 
definitive family history and pathologic features (28).
Since release of the 2005 recommendation, the USPSTF increased-risk family history 
patterns appear to have been viewed by some health professionals as the "criteria" or "gold 
standard" for determining appropriateness of genetic counseling referral (17, 19, 21, 29), and 
in some cases to determine who should be tested for BRCA1/2 mutations (30). If the 
USPSTF increased-risk family history patterns are taken as the basis for referral and 
insurance coverage for genetic counseling and genetic testing, it could result in lack of 
access to these services for those at substantial risk (e.g., women with breast cancer and 
positive family histories) and over-referral of women unlikely to carry a BRCA1/2 mutation 
(e.g., a woman with 3 second-degree relatives diagnosed with breast cancer after the age of 
70 years). It needs to be emphasized that USPSTF did not attempt to address the merits or 
disadvantages of referral and testing of affected women, which should not be construed to 
imply that such services are inappropriate. There is a substantial body of literature regarding 
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the importance of identifying women with breast cancer who carry BRCA1/2 mutations with 
respect to surgical management (lumpectomy vs. bilateral mastectomy), MRI screening for 
second primary breast cancers, prevention of ovarian cancer, as well as emerging data on 
differential treatment with PARP2 inhibitors (31). Other recognized guidelines, including 
those of the NCCN (28, 32), specifically focus on issues of referral and testing of affected 
women. Finally, insofar, as our data and others suggest that substantially more than 2% of 
women will meet one of these patterns, and given the recognized limitations of access to 
qualified genetics professionals, especially in rural areas, serious consideration will need to 
be given to increasing the number of genetic service providers and developing alternative 
service delivery models.
Several strengths of this study are worth noting. First, the survey was conducted in a large, 
racially diverse managed care population. Much of the research on genetic risk and 
counseling has been conducted among women from high-risk families attending specialized 
clinics, who may differ from those receiving care in community settings (33). Our 
population provided a reasonable compromise between a general population-based survey 
and a clinic-based survey. While this sample cannot be assumed to be fully representative of 
women in the general population, it does reflect the population of women with access to 
medical care including genetic counseling and BRCA1/2 testing. A second strength was our 
use of an eligibility-screening interview, which allowed preliminary classification into risk 
groups for sampling purposes. Finally, a response rate of 76.3% was achieved for the full 
interview.
Study limitations include self-report of genetic counseling referral, BRCA1/2 testing, 
positive test results, and family cancer history. Depending on self-report might have led to 
biased results with respect to prevalence of genetic counseling referral and BRCA testing, 
although detailed description of these processes were provided by the interviewers. In 
addition, only 0.3% and 4% of survey respondents answered "don’t know" to the questions 
regarding counseling referral and BRCA testing, respectively, and no subject refused to 
answer. In contrast, 10.5% of women who reported BRCA testing indicated they did not 
know their results, though only one refused to answer. These response patterns suggest that 
our findings might reflect a small bias toward underestimation of the prevalence of BRCA 
testing in this population. With respect to family history, sharing cancer information within 
families and the accuracy of reporting depends on multiple factors such as geographical 
distance, familial culture of communication, degree of relatedness, gender, and knowledge 
about cancer (34–36). Reporting of first-degree relatives and breast cancer is generally more 
accurate than reporting of second-degree relatives and other cancers (37–39), with ovarian 
cancer often underreported (38, 39). Because the USPSTF risk classification depends on the 
number and relatedness of affected relatives, an under-reporting of ovarian cancer may have 
led to an underestimation of the number of women at high-risk. Another potential source of 
underestimation of women at high-risk was the exclusion of women with a prior 
oophorectomy or personal history of ovarian cancer from the survey, although ovarian 
cancer survivors comprise less than 0.2% of women aged 30 or more in the United States 
(40).
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To address these limitations, future studies should include women with a personal history of 
ovarian cancer or prior oophorectomy, and in at least a subset of the population, medical 
record verification of reported cancers, completion of genetic counseling, and BRCA1/2 
testing results in participants and family members. Factors influencing physician referral for 
genetic counseling, and the roles of the healthcare system, healthcare provider, and patient 
characteristics in both referral and uptake of genetic counseling and BRCA1/2 testing should 
also be evaluated. Finally, these study findings suggest that further research is needed to 
examine the effectiveness of using the USPSTF patterns in identifying those appropriate for 
genetic counseling referral.
In summary, this study involving 2,524 female participants from a large integrated 
healthcare system showed both a significantly higher percentage of women at potential risk 
for hereditary breast/ovarian cancer based on family history than that originally predicted in 
the USPSTF 2005 recommendations, and evidence of significant underreferral of high-risk 
women for cancer genetic counseling despite in-system availability of these services. These 
findings indicate that efforts directed toward improving provider education and increasing 
the cancer genomics workforce are needed. Such efforts, further strengthened by a focus on 
enhancing public awareness of the importance of family history and the availability of 
genetic counseling and testing will be needed if the potential benefits of identification and 
management of individuals and families who are impacted by the presence of a BRCA1/2 
mutation are to be realized.
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Table 1
USPSTF increased-risk family history patterns (1)
Non-Ashkenazi Jewish Women:
1 Two first-degree relatives with breast cancer, 1 of whom received the diagnosis at age 50 years or younger
2 A combination of 3 or more first- or second-degree relatives with breast cancer regardless of age at diagnosis
3 A combination of both breast and ovarian cancer among first- and second-degree relatives
4 A first-degree relative with bilateral breast cancer
5 A combination of 2 or more first- or second-degree relatives with ovarian cancer regardless of age at diagnosis
6 A first- or second-degree relative with both breast and ovarian cancer at any age
7 A history of breast cancer in a male relative
Women of Ashkenazi Jewish Heritage:
8 Any first-degree relative (or 2 second-degree relatives on the same side of the family) with breast or ovarian cancer
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Table 2
Prevalence of participants meeting USPSTF increased-risk family history patterns
USPSTF Increased-risk family history pattern
All participantsa (n = 2,524) 
%
Participants without breast 
cancer (n = 2,087) %
Any pattern 5.9 5.0
Two first-degree relatives with breast cancer, at least 1 relative under age 50 1.4 0.9
Three or more first- or second-degree relatives with breast cancer at any age 1.8 1.4
Both breast and ovarian cancer among first- and second-degree relatives 2.6 2.3
A first-degree relative with bilateral breast cancer 1.1 1.0
Two or more first- or second-degree relatives with ovarian cancer any age 0.8 0.8
A first- or second-degree relative with both breast and ovarian cancer 0.2 0.2
Male relative with breast cancer 0.5 0.5
Any 2 patterns 1.5 1.1
Any 3 or more patterns 0.6 0.5
Jewish pattern 0.4 0.3
NOTE: All prevalence estimates are weighted to account for the oversampling of high and elevated objective risk group.
a
Includes participants with a personal history of breast cancer considered from the perspective of a hypothetical unaffected sister.
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